Journal article
Sickle cell disease: Its molecular mechanism and the one drug that treats it
International journal of biological macromolecules, v 93(Pt A), pp 1168-1173
Dec 2016
PMID: 27667542
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Sickle cell disease is probably the first known assembly disease, and its mechanism has been extensively studied. It arises because of the expression of a mutant hemoglobin that can polymerize, and which does so by a double nucleation mechanism that is now seen to operate in other diseases. The polymers so formed lead to circulatory obstruction in the microcirculation. The accuracy of the description that has been developed is sufficient to describe precisely the impact of molecules that cannot join polymers but that still crowd the solution, including fetal hemoglobin. The one approved drug, hydroxyurea, is thought to achieve its benefit by enhancing the production of fetal hemoglobin, but the effects of the drug on polymerization exceed what the added fetal hemoglobin can accomplish. While some possible answers to this mystery are suggested, no mechanism has been conclusively established for the remarkably efficacy of the one drug available to treat this disease.
Metrics
Details
- Title
- Sickle cell disease: Its molecular mechanism and the one drug that treats it
- Creators
- Frank A. Ferrone - Drexel University
- Publication Details
- International journal of biological macromolecules, v 93(Pt A), pp 1168-1173
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Physics
- Web of Science ID
- WOS:000389090900135
- Scopus ID
- 2-s2.0-84988948545
- Other Identifier
- 991019169814204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Biochemistry & Molecular Biology
- Chemistry, Applied
- Polymer Science